Biotech · Private company
Senhwa Biosciences, Inc.
Track this companyFree. Adds Senhwa Biosciences, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials51 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- CisplatinPhase 2 · CholangiocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- CX-4945Phase 2 · CholangiocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- GemcitabinePhase 2 · CholangiocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- SilmitasertibPhase 2 · Covid19ClinicalTrials.gov · fetched Nov 12, 2026
- SOCPhase 2 · Covid19ClinicalTrials.gov · fetched Nov 12, 2026
- CX-4945Phase 1 · Carcinoma, Basal CellClinicalTrials.gov · fetched Nov 12, 2026
- CX-5461Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) MutationPHASE1 · RECRUITING · started Sep 8, 2021ClinicalTrials.gov NCT04890613 · fetched Nov 12, 2026
- Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)PHASE2 · TERMINATED · started Jan 21, 2021ClinicalTrials.gov NCT04668209 · fetched Nov 12, 2026
- Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19PHASE2 · COMPLETED · started Nov 30, 2020ClinicalTrials.gov NCT04663737 · fetched Nov 12, 2026
- Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)PHASE1 · COMPLETED · started Apr 16, 2019ClinicalTrials.gov NCT03897036 · fetched Nov 12, 2026
- Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of CholangiocarcinomaPHASE1_PHASE2 · COMPLETED · started Jun 1, 2014ClinicalTrials.gov NCT02128282 · fetched Nov 12, 2026